- Home
- PMAX vs INKT Comparison
PMAX vs INKT Comparison
Compare PMAX & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMAX | INKT |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 51.7M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PMAX | INKT |
|---|---|---|
| Price | $2.29 | $11.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.7M | 21.3K |
| Earning Date | 09-23-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,799,100.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.56 | $4.56 |
| 52 Week High | $24.36 | $76.00 |
Technical Indicators
Market Signals| Indicator | PMAX | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 45.91 |
| Support Level | $2.30 | $11.55 |
| Resistance Level | $2.97 | $12.68 |
| Average True Range (ATR) | 0.36 | 0.87 |
| MACD | -0.02 | 0.14 |
| Stochastic Oscillator | 37.65 | 44.52 |
Price Performance
Historical ComparisonAbout PMAX Powell Max Limited
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.